Fundamental Analysis of CYTOMX THERAPEUTICS INC(NASDAQ:CTMX) stock

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to CTMX. CTMX was compared to 588 industry peers in the Biotechnology industry. CTMX may be in some trouble as it scores bad on both profitability and health. CTMX is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year CTMX has reported negative net income.

CTMX had a negative operating cash flow in the past year.

In the past 5 years CTMX always reported negative net income.

In the past 5 years CTMX reported 4 times negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -0.28%, CTMX belongs to the top of the industry, outperforming 93.86% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-0.28%
ROE	N/A
ROIC	N/A

ROA(3y)-24.16%

ROA(5y)-22.32%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

CTMX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

CTMX does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for CTMX has been increased compared to 1 year ago.

CTMX has more shares outstanding than it did 5 years ago.

There is no outstanding debt for CTMX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

CTMX has an Altman-Z score of -3.74. This is a bad value and indicates that CTMX is not financially healthy and even has some risk of bankruptcy.

With a Altman-Z score value of -3.74, CTMX perfoms like the industry average, outperforming 40.44% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-3.74

ROIC/WACCN/A

WACC9.22%

2.3 Liquidity

A Current Ratio of 1.17 indicates that CTMX should not have too much problems paying its short term obligations.

The Current ratio of CTMX (1.17) is worse than 86.69% of its industry peers.

A Quick Ratio of 1.17 indicates that CTMX should not have too much problems paying its short term obligations.

CTMX's Quick ratio of 1.17 is on the low side compared to the rest of the industry. CTMX is outperformed by 85.84% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.17
Quick Ratio	1.17

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 98.68% over the past year.

Looking at the last year, CTMX shows a very strong growth in Revenue. The Revenue has grown by 197.76%.

Measured over the past years, CTMX shows a quite strong growth in Revenue. The Revenue has been growing by 11.21% on average per year.

EPS 1Y (TTM)98.68%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q102.33%

Revenue 1Y (TTM)197.76%

Revenue growth 3Y0.27%

Revenue growth 5Y11.21%

Revenue growth Q2Q2700.74%

3.2 Future

The Earnings Per Share is expected to decrease by -78.97% on average over the next years. This is quite bad

Based on estimates for the next years, CTMX will show a decrease in Revenue. The Revenue will decrease by -3.33% on average per year.

EPS Next Y-858.8%

EPS Next 2Y-333.57%

EPS Next 3Y-239.9%

EPS Next 5Y-78.97%

Revenue Next Year-5.3%

Revenue Next 2Y-9.98%

Revenue Next 3Y-22.45%

Revenue Next 5Y-3.33%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CTMX. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CTMX. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as CTMX's earnings are expected to decrease with -239.90% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-333.57%

EPS Next 3Y-239.9%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

CTMX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CYTOMX THERAPEUTICS INC

NASDAQ:CTMX (5/3/2024, 7:00:01 PM)

After market: 4.69 +0.26 (+5.87%)

4.43

-0.07 (-1.56%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap300.04M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-0.28%
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.5

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	1.17
Quick Ratio	1.17
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)98.68%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-858.8%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)197.76%

Revenue growth 3Y0.27%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

CYTOMX THERAPEUTICS INC (CTMX)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens